FLYRCADO

Growth

flurpiridaz f-18

NDAINTRAVENOUSSOLUTION

Approved

Sep 2024

Lifecycle

Growth

Competitive Pressure

0/100

Mechanism of Action

Positron Emitting Activity

Pharmacologic Class:

Radioactive Diagnostic Agent

Loss of Exclusivity

LOE Date

May 13, 2042

197 months away

Patent Expiry

May 13, 2042

Exclusivity Expiry

Sep 27, 2029

Patent Records (5)

Patent #	Expiry	Type	Use Code
9161997	Feb 4, 2026Expired	SubstanceProduct	U-4011
7344702	May 26, 2026	Substance	—
8226929	Jun 21, 2028		U-4011
9603951	May 2, 2031		U-4011
8936777	Jun 30, 2031		U-4011

External Resources

Full prescribing information

FDA approval history

Drug nomenclature & identifiers